Table 1: Patient characteristics at baseline.

Included patient population for TVR/PegIFN/RBV triple therapy ()

Age (years), mean ± SD51.8 ± 10.5
Gender (male)7 (58%)
Body mass index (kg/m2), mean ± SD26.4 ± 5.3
HCV genotype
 1a2 (17%)
 1b10 (83%)
Previous PegIFN/RBV therapy after OLT
 Naive5 (42%)
 Nonresponder/relapsers7 (58%)
Time between OLT and beginning TVR/PegIFN/RBV therapy (months), mean ± SD63.7 ± 61.4
Fibrosis grade
 1 4 (33%)
 2 5 (42%)
 33 (25%)
HCV viral load (log 10 IU/mL), mean ± SD6.1 ± 0.8
Bilirubin (μmol/L), mean ± SD23.9 ± 13.7
ALT (μkat/L), mean ± SD0.99 ± 0.84
Glomerular filtration rate (mL/min/1.73 m2), mean ± SD72.0 ± 20.4
Hemoglobin (mmol/L), mean ± SD7.33 ± 1.43
White blood cell count (/nL), mean ± SD4.8 ± 1.9
Platelet count (/nL), mean ± SD222.3 ± 105.9